Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akorn, Inc.    AKRX

AKORN, INC. (AKRX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
4.46(c) 4.29(c) 4.33(c) 4.52(c) 4.55 Last
4 480 919 3 390 257 4 722 882 3 734 214 1 144 828 Volume
+4.69% -3.81% +0.93% +4.39% +0.66% Change
More quotes
Financials (USD)
Sales 2018 706 M
EBIT 2018 -164 M
Net income 2018 -223 M
Finance 2018 497 M
Yield 2018 -
Sales 2019 672 M
EBIT 2019 48,9 M
Net income 2019 -91,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0,10x
Capi. / Sales2019 0,84x
Capitalization 567 M
More Financials
Company
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The... 
Sector
Pharmaceuticals
Calendar
12/27Shareholder meeting
More about the company
Surperformance© ratings of Akorn, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AKORN, INC.
12/10ROBBINS ARROYO LLP : Shareholder Lawsuit Filed Against Officers and Directors of..
BU
12/10AKORN : Supreme Court of the State of Delaware Rules against Akorn, New CEO Sear..
AQ
12/10MANAGEMENT TRACKS : MiMedx, Akorn, Mallinckrodt
AQ
12/08AKORN : Supreme Court of the State of Delaware Rules Against Akorn, New CEO Sear..
AQ
12/08AKORN : Report of unscheduled material events or corporate event
PU
12/07Akorn CEO Retires Following Court Ruling
DJ
12/07AKORN INC : Change in Directors or Principal Officers, Regulation FD Disclosure,..
AQ
12/07Supreme Court of the State of Delaware Rules Against Akorn, New CEO Search Un..
GL
12/07Delaware Supreme Court Upholds Ruling Allowing Fresenius to End Akorn Deal --..
DJ
12/07Delaware Supreme Court Upholds Ruling Allowing Fresenius to End Akorn Deal
DJ
More news
Analyst Recommendations on AKORN, INC.
More recommendations
Sector news : Pharmaceuticals - NEC
01:29pMERCK AND : bolsters animal health unit with $2.4 billion Antelliq purchase
RE
11:26aThyssenkrupp fills key management posts after year of turmoil
RE
11:26aThyssenkrupp fills key management posts after year of turmoil
RE
08:55aTHYSSENKRUPP : to Appoint Johannes Dietsch as CFO
DJ
08:48aJOHNSON & JOHNSON : J&J Pulled Into Court Fight
DJ
More sector news : Pharmaceuticals - NEC
Chart AKORN, INC.
Duration : Period :
Akorn, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKORN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 8,00 $
Spread / Average Target 77%
EPS Revisions
Managers
NameTitle
Rajat Rai Chief Executive Officer
Alan D. Weinstein Chairman
Bruce Kutinsky Chief Operating Officer
Duane A. Portwood CFO & Executive Vice President
Mark M. Silverberg Executive VP-Operations & Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
AKORN, INC.-86.57%567
JOHNSON & JOHNSON5.81%396 504
PFIZER21.92%258 506
NOVARTIS6.21%224 691
ROCHE HOLDING LTD.3.12%220 215
MERCK AND COMPANY40.41%205 456